Literature DB >> 14759358

Antiphospholipid antibodies and stroke.

Stanley Tuhrim1.   

Abstract

Antiphospholipid antibodies are associated with venous and arterial thrombo-occlusive events, including stroke. They are a heterogeneous family of antibodies that react to negatively charged membrane-bound phospholipids or phospholipid-protein complexes. Despite much progress in the past decade, the precise mechanisms by which they promote thrombosis remain unknown. Increased risk of initial, but perhaps not recurrent, stroke has been associated with their presence. Antithrombotic regimens have been the mainstay of treatment, but the ideal therapeutic approach remains to be defined. This paper reviews the history, definition, associations, and treatment of this complex entity.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14759358     DOI: 10.1007/s11886-004-0011-1

Source DB:  PubMed          Journal:  Curr Cardiol Rep        ISSN: 1523-3782            Impact factor:   2.931


  32 in total

1.  Seasonal distribution of antiphospholipid antibodies.

Authors:  T H Luong; J H Rand; X X Wu; J H Godbold; M Gascon-Lema; S Tuhrim
Journal:  Stroke       Date:  2001-08       Impact factor: 7.914

2.  The natural history of systemic lupus erythematosus: an approach to its study through chronic biologic false positive reactors.

Authors:  J E MOORE; W B LUTZ
Journal:  J Chronic Dis       Date:  1955-03

3.  Anticardiolipin antibodies: a study of frequency in TIA and stroke.

Authors:  D C Hess; J Krauss; R J Adams; F T Nichols; D Zhang; H A Rountree
Journal:  Neurology       Date:  1991-04       Impact factor: 9.910

4.  Antiphospholipid antibodies: an elderly statesman Dons new garments.

Authors:  E N Harris; G R Hughes; A E Gharavi
Journal:  J Rheumatol Suppl       Date:  1987-06

5.  IgG anticardiolipin antibody titer > 40 GPL and the risk of subsequent thrombo-occlusive events and death. A prospective cohort study.

Authors:  S R Levine; L Salowich-Palm; K L Sawaya; M Perry; H J Spencer; H J Winkler; Z Alam; J L Carey
Journal:  Stroke       Date:  1997-09       Impact factor: 7.914

Review 6.  Molecular pathogenesis of the antiphospholipid syndrome.

Authors:  Jacob H Rand
Journal:  Circ Res       Date:  2002-01-11       Impact factor: 17.367

7.  beta(2)-Glycoprotein 1-dependent anticardiolipin antibodies and risk of ischemic stroke and myocardial infarction: the honolulu heart program.

Authors:  R L Brey; R D Abbott; J D Curb; D S Sharp; G W Ross; C L Stallworth; S J Kittner
Journal:  Stroke       Date:  2001-08       Impact factor: 7.914

8.  Anticardiolipin antibodies and the risk of recurrent thrombo-occlusive events and death. The Antiphospholipid Antibodies and Stroke Study Group (APASS).

Authors: 
Journal:  Neurology       Date:  1997-01       Impact factor: 9.910

9.  Anti-cardiolipin antibodies and risk of myocardial infarction in a prospective cohort of middle-aged men.

Authors:  O Vaarala; M Mänttäri; V Manninen; L Tenkanen; M Puurunen; K Aho; T Palosuo
Journal:  Circulation       Date:  1995-01-01       Impact factor: 29.690

10.  Antiphospholipid antibodies and stroke in young women.

Authors:  Robin L Brey; Christian L Stallworth; David L McGlasson; Marcella A Wozniak; Robert J Wityk; Barney J Stern; Michael A Sloan; Roger Sherwin; Thomas R Price; Richard F Macko; Constance J Johnson; Christopher J Earley; David W Buchholz; J Richard Hebel; Steven J Kittner
Journal:  Stroke       Date:  2002-10       Impact factor: 7.914

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.